MedPath

Summit Therapeutics' Lung Cancer Drug Ivonescimab Receives FDA Fast Track Designation

  • Summit Therapeutics' stock experienced a surge following the FDA's Fast Track designation for its lung cancer drug, ivonescimab, indicating accelerated review potential.
  • The company has completed enrollment for a Phase 3 trial of ivonescimab, involving patients across North America, Europe, and China, marking its first global study.
  • Ivonescimab has been previously administered to over 1,800 patients, and positive results from earlier trials significantly boosted Summit's stock value.
Summit Therapeutics (SMMT) announced that its investigational lung cancer drug, ivonescimab, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). This designation aims to expedite the development and review of drugs intended to treat serious conditions and address unmet medical needs.

Phase 3 Trial Enrollment Completed

In addition to the Fast Track designation, Summit Therapeutics has completed enrollment for its Phase 3 clinical trial of ivonescimab. This trial encompasses patients from North America, Europe, and China, representing the company's first global study of the drug. Ivonescimab has been administered to over 1,800 patients in prior trials, demonstrating its potential in treating lung cancer.

CEO's Perspective

"As our belief in the potential for ivonescimab to make a meaningful, positive difference continues to grow, we are pleased that the FDA has granted Fast Track designation for ivonescimab," said Summit Chief Executive Officer (CEO) Robert Duggan.

Impact of Previous Trial Results

Positive results from a previous trial in China caused Summit's stock to more than double in value over five trading sessions last month, reaching a record close of $31.93. While the stock has since retreated, the Fast Track designation has provided another boost, with shares up 13% to $21.05 soon after markets opened Friday.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves Checkpoint Therapeutics' Unloxcyt (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma

The FDA has granted approval to Checkpoint Therapeutics' Unloxcyt (cosibelimab-ipdl) for the treatment of advanced cutaneous squamous cell carcinoma (cSCC).

Lantern Pharma's LP-184 Receives FDA Fast Track Designation for Triple-Negative Breast Cancer

Lantern Pharma's LP-184 has been granted Fast Track designation by the FDA for treating triple-negative breast cancer, marking its second such designation in 2024.

Biofrontera's Ameluz Demonstrates High Efficacy in Phase III sBCC Trial

Biofrontera's Ameluz-PDT therapy met the primary endpoint, showing 65.5% success in complete clearance of superficial basal cell carcinoma (sBCC) lesions, compared to 4.8% with placebo.

Shuttle Pharmaceuticals' Ropidoxuridine Shows Promise in Phase 2 Glioblastoma Trial

Shuttle Pharmaceuticals has successfully dosed the first three patients in a Phase 2 trial of ropidoxuridine for glioblastoma.

Sangamo Therapeutics' Fabry Disease Candidate ST-920 Gains Accelerated Approval Pathway

Sangamo Therapeutics' shares surged after the FDA agreed to a regulatory pathway for accelerated approval of isaralgagene civaparvovec (ST-920) for Fabry disease.

Summit Therapeutics Completes Enrollment in Phase 3 HARMONi Trial for Ivonescimab in Lung Cancer

Summit Therapeutics completed patient enrollment for its Phase 3 HARMONi trial, evaluating ivonescimab plus chemotherapy for EGFR-mutated NSCLC.

Akeso's Ivonescimab Demonstrates Superiority Over Pembrolizumab in Lung Cancer Trial

Akeso's Ivonescimab showed a notable increase in progression-free survival compared to Merck's Keytruda (pembrolizumab) in a Phase III clinical trial for lung cancer.

Strides Pharma Receives USFDA Approval for Generic Theophylline Extended-Release Tablets

Strides Pharma's subsidiary secures USFDA approval for generic Theophylline extended-release tablets, used for chronic asthma and lung diseases.

FDA Grants Fast Track Designation to Immuneering's IMM-1-104 for Pancreatic Cancer

The FDA has granted Fast Track designation to Immuneering's IMM-1-104 for pancreatic ductal adenocarcinoma after one prior line of therapy.

4DMedical, TrivarX, and Artrya Advance with FDA Clearances and US Partnerships

4DMedical's CT LVAS receives FDA clearance, expanding functional lung imaging accessibility in the US after its Australian rollout.

Reference News

[1]
Summit Therapeutics Stock Jumps as Lung Cancer Drug Placed on FDA Fast Track
investopedia.com · Oct 4, 2024

Summit Therapeutics' stock surged after FDA granted Fast Track designation to its lung cancer drug. The company complete...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy